Exploratory Biomarker Analysis of PD-1/CTLA-4 Bispecific Antibody Therapy Response in PD-L1-Negative Advanced Non-Small Cell Lung Cancer: Genomic and Transcriptomic Profiling from the Phase II LungCadX Study
Wang Li, Chunxia Su(Tongji University), Minwei Bao(Tongji University), Changbin Zhu(Dian Diagnostics (China)), Chuangzhou Rao(Ningbo No. 2 Hospital), Zhixuan Ren(Fudan University), Li Liu(Air Force Medical University), Tianqing Chu, Jialin Qu(Chongqing Medical University), Jia-Ning Chen(Shanghai Jiao Tong University), Shuai Lv(University of Science and Technology of China), Qi Wang(Tongji University)
Cited by 0
Related Papers
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
|Cancer Discovery|2023|190
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
|Lung Cancer|2013|178
Pan-cancer analysis of <i>ARID1A</i> Alterations as Biomarkers for Immunotherapy Outcomes
|Journal of Cancer|2019|142